Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

Global Immunotherapy Drugs Market to 2025: Market will Grow at a CAGR of 12.5% - Key Vendors are AbbVie, Amgen, F. Hoffmann-La Roche, Bristol-Myers Squibb, Johnson & Johnson, & Merck & Co

DUBLIN, June 5, 2019 /PRNewswire/ -- The "Global Immunotherapy Drugs Market - Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025" report has been added to ResearchAndMarkets.com's offering. The introduction of a novel product with affordable drug cost is expected to increase the competition among the market players.Many companies are currently focused on approvals, collaboration, and development of new products related to immunotherapy drugs due to increased demand for this therapy to treat various disease types.For instance, in January 2019, BioNTech AG inked a deal with MAB Discovery GmbH to acquire MAB's operational antibody generation unit. The acquisition helps to expand BioNTech, which is a top privately-held developer of RNA-based therapeutics, further into monoclonal antibody (mAb) development to develop new treatments that combine technologies of both the companies. In June 2018, Novartis received European approval for Aimovig, for the prevention of migraine in adults, and it works by blocking the activity of calcitonin gene-related peptide (CGRP) that is involved in migraine attacks.

First found on: finance.yahoo.com And then on: 2 other references